Skip to main content

06-10-2019 | Dulaglutide | ADA 2019 | Article

Expert commentary: The REWIND trial

John Wilding discusses how the results of the REWIND study add to our knowledge of the effects of the glucagon-like peptide-1 receptor agonist class in people with varying degrees of cardiovascular risk (3:37).

Related topics